MOLECULAR PATHWAYS AND BIOMARKERS (MPB)

分子通路和生物标志物 (MPB)

• 批准号: 8089520
• 负责人: ERWIN G VAN MEIR
• 金额: $ 8.71万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8089520
• 关键词: Accounting; Animal Model; Antineoplastic Agents; Area; Basic Science; Biological Markers; Biology; Blood; Blood Vessels; Cells; Characteristics; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Detection; Development; Diagnosis; Distant; Event; Fibroblasts; Funding; Grant; Growth; Human; Hypoxia; Image; Imaging technology; Inflammatory; Investigation; Knowledge; Malignant Neoplasms; Mediator of activation protein; Molecular; Neoplasm Metastasis; Outcome; Pathway interactions; Patients; Peer Review; Primary Neoplasm; Proteome; Publications; Publishing; Signal Pathway; Signal Transduction; Site; Smooth Muscle; Specimen; Stromal Cells; Stromal Neoplasm; Techniques; Testing; Therapeutic Agents; Tissues; Translations; Tumor Angiogenesis; angiogenesis; bone; cancer cell; cancer diagnosis; cancer type; disorder prevention; drug development; follow-up; medical schools; member; novel; novel therapeutics; outcome forecast; pre-clinical; programs; response; therapeutic target; tool; tumor; tumor growth

Program 2. Molecular Pathways and Biomarkers (MPB) The abnormal function of cancer cells can be investigated through the understanding of the changes in the activation and silencing of homeostatic cell signaling events. Identification of the functional proteome characteristic of a cancer cell permits the understanding of its underlying biology and provides unique opportunities for therapeutic targeting of critical node points as well as exploitation of biomarkers for disease prevention, detection and follow-up. The primary themes of the Molecular Pathways and Biomarkers program are in three main areas and reflect a major emphasis on basic science investigations of the cancer signalosome and its exploitation for clinical translation. The MPB Program's thematic areas include (1) tumor hypoxia and angiogenesis; (2) tumor-stroma interactions and (3) development of novel imaging technology and applications. The aims of the MPB program are: (i) to elucidate the mechanisms of the cellular signaling events that underlie angiogenesis and their targeting for therapy. (ii) To discover the key mediators of tumor-stromal interactions and identify biomarkers that predict primary tumor growth and metastasis at distant sites. (iii) To develop novel imaging applications to better detect cancer growth, help diagnose cancer type and provide more accurate tools for treatment follow-up. The MPB program is comprised of 40 core members from 15 departments within the School of Medicine. Currently there are 30 funded program core members. The total peer-reviewed funding per year of MPB is $15.23 M ($10.6 million direct), of which NCI funding represents $4.8 M ($3.3 M direct). In the P20 planning grant period of 2002-2008, MPB members published 445 articles. Intraprogrammatic collaborations accounted for 110 (24.7%) and interprogrammatic collaborations accounted for 144 (32.4%) of these publications.

方案2.分子途径和生物标志物（MPB） 癌细胞的异常功能可以通过了解癌细胞的细胞周期的变化来研究。 稳态细胞信号传导事件的激活和沉默。功能蛋白质组鉴定 癌细胞的特征允许了解其潜在的生物学，并提供独特的 关键节点的治疗靶向以及疾病生物标志物的开发的机会 预防、检测和跟踪。分子途径和生物标志物的主要主题 该计划主要包括三个方面，反映了对癌症基础科学研究的主要重视。 信号体及其在临床翻译中的应用。MPB计划的主题领域包括（1）肿瘤 缺氧和血管生成;（2）肿瘤-间质相互作用和（3）新成像技术的发展 和应用 MPB计划的目标是： (i)阐明血管生成及其靶向的细胞信号传导机制 治疗 (ii)发现肿瘤间质相互作用的关键介质，并确定预测原发性肿瘤的生物标志物。 肿瘤生长和远处转移。 (iii)开发新的成像应用程序，以更好地检测癌症生长，帮助诊断癌症类型， 为后续治疗提供更准确的工具。 MPB计划由来自医学院15个部门的40名核心成员组成。 目前有30个资助项目的核心成员。MPB每年的同行评审资金总额为 1523万美元（直接1060万美元），其中NCI资金为480万美元（直接330万美元）。在P20规划中 2002-2008年资助期间，MPB成员发表了445篇文章。方案内协作 其中，110项（24.7%）是方案间合作，144项（32.4%）是方案间合作。 出版物。